This study is looking at Chronic Obstructive Pulmonary Disease, which is a lung condition that makes it hard to breathe and causes symptoms like coughing and shortness of breath. The study will test a medication called depemokimab, which is given as an injection under the skin. Some people in the study will receive depemokimab while others will receive placebo. People taking part will also continue using their regular inhaled medicines, which include salbutamol for quick relief of breathing problems and a combination of inhaled medications that help keep the airways open and reduce inflammation in the lungs. The study will also use a sterile 0.9% sodium chloride solution, which is a salt water solution.
The purpose of the study is to find out if depemokimab works better than placebo in treating people with this lung disease who have a type of inflammation called Type 2 inflammation. The study will look at whether the medication can reduce the number of times symptoms suddenly get worse, which doctors call exacerbations. These are times when breathing problems become much worse and may need treatment with antibiotics or steroid pills, or sometimes even a visit to the emergency room or hospital.
During the study, people will receive treatment for up to 104 weeks, which is about two years. The doctors will check how often breathing problems get worse, how long it takes before problems get worse, and how the disease affects daily life and breathing symptoms. The study will compare results between people receiving depemokimab and those receiving placebo to see if the medication helps reduce flare-ups and improves quality of life for people with this lung condition.
Austria 
Bulgaria 
Czechia 
Germany 
Greece 
Italy 
Latvia 
Romania 
